Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...